Tarrytown's Regeneron presented some promising data Tuesday from its antibody cocktail.
According to its own research, the company's antibody cocktail cut the risk of death by 50% in patients currently in the hospital that require low-flow oxygen.
Initial data showed it had to be used in non-hospitalized patients only.
Last month, the FDA granted an emergency-use authorization for the antibody cocktail.